Mach7 Technologies Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a M7T.AX research report →
Price Chart
About the company
Mach7 Technologies Limited develops and commercializes medical imaging and data management software solutions for healthcare organizations in North America, the Asia Pacific, the Middle East, Europe, and internationally. It offers eUnity enterprise diagnostic viewer, a zero-footprint viewer that allows medical professionals to remotely access patients’ medical images; vendor-neutral archive (VNA), a vendor-agnostic data management solution, which includes administration tools that allow for the storage, access, retrieval, and viewing of images across a healthcare network. The company also provides workflow applications, such as a universal worklist, quality control (QC) tools designed for technologists’ workflows; image sharing and exchange capabilities; teleradiology services; and additional specialized tools to serve departmental patient care needs.
- CEO
- Teri Thomas
- IPO
- 2005
- Employees
- 167
- HQ
- South Burlington, VT, US
Get TickerSpark's AI analysis on M7T.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $66.98M
- P/E
- -6.69
- PEG
- 0.09
- P/S
- 2.26
- P/B
- 1.72
- EV/EBITDA
- -7.75
- Div Yield
- 0.00%
- Gross Margin
- 5.17%
- Op Margin
- -36.18%
- Net Margin
- -33.94%
- ROE
- -23.86%
- ROIC
- -25.36%
Latest fiscal year · YoY change
- Revenue
- $33.79M+95.9%
- Gross Profit
- $8.38M+230.6%
- Op Income
- $-8,422,053
- Net Income
- $-6,201,404+22.2%
- EPS
- $-0.03+22.1%
- OCF Growth
- -74.8%
- FCF Growth
- -96.6%
- 52W High
- $0.69
- 52W Low
- $0.24
- 50D MA
- $0.30
- 200D MA
- $0.36
- Beta
- 0.97
- RSI (14)
- 47
- Avg Volume
- 155.64K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Mach7 said first-half FY26 results were held back by a commercial reset, but management highlighted stronger pipeline discipline, early Flamingo traction, and a path back to growth next year.· February 26, 2026
- First-half revenue was $13.7 million, down 23% on PCP, as lower capital license activity reflected the strategic reset.
- Recurring revenue was $11.6 million and 85% of total revenue; gross margin stayed high at 92%.
- Operating expenses fell 6%, and the company ended the half with $18.5 million in cash and no debt.
- Management said the first new logo in quite a while closed in the half, and pipeline quality improved with net new CARR pipeline for new logos up 30% over the last 3 months.
- Teri Thomas said FY26 revenue should be roughly flat year over year, with growth expected to resume in FY27 as commercial momentum builds.
Mach7 reported first-half FY26 revenue of $13.7 million, down 23% on PCP. Recurring revenue was $11.6 million, down 8% from PCP, and represented 85% of total revenue. Total CARR was $26.1 million and ARR run rate was $23 million; Daniel Lee said those were down 12% and 2%, respectively, on a constant currency basis. Gross margin was 92%, operating expenses decreased 6%, cash receipts were $12.5 million, and the company ended the half with $18.5 million in cash and 0 debt. Management said sales orders totaled $10 million in contract value, with 85% of sales orders recurring, and product revenue was split 55/45 between VNA and the eUnity Viewer. For the second half, Teri Thomas guided to revenue roughly even with last year, noting this depends partly on capital deals likely out of Asia and services opportunities; she said next year should be a year of growth.
Teri Thomas framed the period as a deliberate reset designed to rebuild Mach7’s commercial engine, sharpen focus, and position the company as a “global imaging EMR.” Her tone was confident and upbeat about the long-term opportunity, even while acknowledging that transformation creates disruption and that sales cycles of 12 to 24 months delay visible impact. She emphasized disciplined growth, a stronger customer-centered operating model, and early evidence that Flamingo and the new commercial approach are resonating.
Daniel Lee said first-half results were affected by lower capital license activity during the reset, but emphasized the business still has a resilient recurring base and strong margins. He cited 85% recurring revenue, 92% gross margin, a 6% decrease in operating expenses, $12.5 million in cash receipts, and $18.5 million in cash with no debt. He also noted that adjusted EBITDA and net profit after tax were pressured by the revenue mix shift, while the cost base realignment should create operating leverage as activity rebuilds in the second half.
Analysts asked how long the reset-driven revenue decline would last, and Teri said FY26 revenue is expected to be roughly flat versus last year, with growth more likely in FY27. On Flamingo, she said modular offerings should expand quarter by quarter over the next 2 years, with internal tracking based on how many deals include Flamingo elements and the win rate on those deals. She also said AI is mostly an opportunity rather than a threat, and that Mach7 is embracing it through partnerships and customer support. In response to a question on eUnityVue, she said Mach7 has not sold it directly yet, but is working through an engagement to make it referenceable and expects a different answer in the future.
The bull case from this call is that Mach7 appears to have stabilized the business fundamentals while rebuilding its sales motion. Management pointed to a 30% increase in net new CARR pipeline for new logos over the last 3 months, first new logo wins in a while, strong 92% gross margin, and a debt-free balance sheet with $18.5 million in cash. Flamingo and the imaging EMR positioning could create new modular revenue streams if the company converts pipeline into closed deals.
The main bear case is that revenue is still declining and management expects FY26 to be only flat year over year, with real growth pushed into FY27. Sales cycles remain long at 12 to 24 months, and the reset included headcount reductions, lower professional services, and weaker capital license sales. Flamingo is still early, eUnityVue has not yet been sold directly, and management acknowledged that the market still needs more awareness of Mach7’s new messaging and products.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 85.1%
- Shares Outstanding
- 235.01M
- Float Shares
- 199.94M
Held by 1 ETFs
Biggest fund positions in M7T.AX by dollar value.
Our M7T.AX coverage
Recent articles, reports, and earnings notes.
No research on M7T.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate M7T.AX report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.